drugset / Trial / NCT02588820
Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection
NaSingle-groupOpen-labelTreatment
Summary
Pilot study to evaluate the impact of extremely early ART in the dynamics of viral reservoir, immune activation and inflammation in patients with HIV-1 infection of less than 20 days (Fiebig stages I-II) compared to patients with infection of 20-100 days (Fiebig stages III-V), to induce HIV functional cure.
Timeline
- Start
- 2016-04
- Primary completion
- 2018-11
- Completion
- 2018-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | 600 mg | — |
| Subject | Darunavir | Small molecule | 800 mg | — |
| Subject | Dolutegravir | Other / unclassified | 50 mg | — |
| Subject | Lamivudine | Other / unclassified | 300 mg | — |
| Subject | Maraviroc | Other / unclassified | 150 mg | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | Tenofovir | Small molecule | 245 mg | — |
| Subject | emtricitabine | Other / unclassified | 200 mg | — |